Abstract
Immune mechanisms have been implicated in chronic viral hepatitis, and these may be influenced by genetic factors. To determine if disease severity in chronic viral hepatitis is associated with the human leukocyte antigens DR3 and/or DR4, 109 patients were evaluated prospectively. The frequencies of DR3 and DR4 in these patients were compared to those in 80 normal subjects. Patients with DR3 and/or DR4 had the same occurrence of severe disease as patients with other DR antigens (21% versus 30%,P=0.3). Patients with DR3, however, had higher serum gamma globulin and immunoglobulin G levels than patients with DR4 and a greater frequency of severe disease (36% vs 12%,P=0.046). Patients with DR4 had concurrent immunologic diseases more commonly than patients with DR3 (44% vs 9%,P=0.005) and patients with other DR antigens (44% vs 9%,P=0.0002). Patients with DR4 but not DR3 had severe disease less frequently than other patients (9% vs 31%,P=0.02). The frequencies of DR3 in patients with severe disease (37% vs 18%,P=0.06) and DR4 in patients without severe disease (44% vs 30%,P=0.07) were different than those in normal subjects but not to a statistically significant level. We conclude that patients with DR3 and DR4 have different clinical and laboratory findings and disease severity. Patients with DR4 have milder disease than patients with other DR antigens. Disease severity, however, is not closely associated with DR3 or DR4.
Similar content being viewed by others
References
Williams RM, Martin S, Falchuk KR, Trey C, Dubey DP, Cannady WG, Fitzpatrick D, Noreen H, Dupont B, Yunis EJ: Increased frequency of HLA-DRW4 in chronic active hepatitis. Vox Sang 35:366–369, 1978
Mackay IR, Tait BD: HLA associations with autoimmune-type chronic active hepatitis: Identification of B8-DRw3 haplotype by family studies. Gastroenterology 79:95–98, 1980
Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R: Susceptibility of autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13:701–706, 1991
Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI: HLA determinants in chronic active liver disease: Possible relation of HLA-Dw3 to prognosis. Tissue Antigens 9:36–40, 1977
Czaja AJ, Rakela J, Hay JE, Moore SB: Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroidtreated severe autoimmune chronic active hepatitis. Gastroenterology 98:1587–1593, 1990
Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH: Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15:215–221, 1992
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502–1507, 1993
Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston ALWF, Mowat AP, Williams R: Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19:609–615, 1994
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 18:816–822, 1993
Hood L, Steinmetz M, Malissen B: Genes of the major histocompatibility complex of the mouse. Annu Rev Immunol 1:529–568, 1983
Magrin S, Craxi A, Fiorentino G, Fabiano C, Provenzano G, Pinzello GB, Palazzo U, Almasio P, Pagliaro L: Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol 13:56–60, 1991
Magrin S, Craxi A, Fabiano C, Fiorentino G, Almasio P, Palazzo U, Pinzello G, Provenzano G, Pagliaro L, Choo Q-L, Kuo G, Polito A, Han J, Houghton M: Hepatitis C virus replication in “autoimmune” chronic hepatitis. J Hepatol 13:364–367, 1991
Cassani F, Muratori L, Manotti P, Lenzi M, Fusconi M, Ballardini G, selleri L, Volta U, Zauli D, Miniero R, Bianchi FB: Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: A reappraisal at the light of hepatitis C virus infection. Gut 33:1260–1263, 1992
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA: Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 18:342–352, 1993
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 108:157–164, 1995
Pawlotsky J-M, Yahia MB, Andre C, Voisin M-C, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani E-S, Duval J, Dhumeaux D: Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 19:841–848, 1994
Tran A, Quaranta J-F, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul J-L, Hebuterne X, Rampal P: High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18:253–257, 1993
Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Willson R: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465–470, 1993
Lisker-Melman M, Webb D, Di Bisceglie AM, Kassianides C, Martin P, Rustgi V, Waggoner JG, Park Y, Hoffnagle JH: Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon. Ann Intern Med 111:479:483, 1989
Baker AL, Kaplan MM, Benz WC, Sidel JS, Wolfe HJ: Polyarteritis associated with Australia antigen-positive hepatitis. Gastroenterology 62:105–110, 1972
Carson CW, Conn DL, Czaja AJ, Wright TL, Brecher ME: Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 20:304–309, 1993
Haddad J, Deny P, Munz-Gotheil C, Ambrosini J-C, Trinchet J-C, Pateron D, Mal F, Callard P, Beaugrand M: Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 339:321–323, 1992
Lunel F, Musset L, Cacoub P, Franguel L, Cresta P, Perrin M, Grippon P, Hoang C, Piette JC, Huraux J-M, Opolon P: Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 106:1291–1300, 1994
Burman P, Totterman TH, Oberg K, Karlsson FA: Thyroid autoimmunity in patients on long term therapy with leukocytederived interferon. J Clin Endocrinol Metab 63:1086–1090, 1986
Mayet W-J, Hess G, Gerken G, Rossol S, Voth R, Manns M, Meyer zum Buschenfelde K-H: Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10:24–28, 1989
Weber P, Weidmann K-H, Klein R, Walter E, Blum HE, Berg PA: Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon. J Hepatol 20:321–328, 1994
Thomas HC, Montano L, Goodall A, de Koning R, Oladapo J, Wiedman KH: Immunological mechanisms in chronic hepatitis B virus infection. Hepatology 2:116S-121S, 1982
Gonzalez-Peralta RP, Davis GL, Lau JYN: Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 21:255–259, 1994
Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF: Autoimmune features as determinants of prognosis in steroidtreated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713–717, 1983
Czaja AJ, Carpenter HA: Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832, 1993
Geall MG, Schoenfield LJ, Summerskill WHJ: Classification and treatment of chronic active liver disease. Gastroenterology 63:458–465, 1972
Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ: Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63:820–833, 1972
Czaja AJ, Wolf AM, Baggenstoss AH: Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 80:687–692, 1981
Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ: Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 3:183–198, 1972
Schalm SW, Korman MG, Summerskill WHJ, Czaja AJ, Baggenstoss AH: Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 22:973–980, 1977
Czaja AJ, Manns MP, Homburger HA: Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103:1290–1295, 1992
Czaja AJ, Nishioka M, Morshed SA, Hachiya T: Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107:200–207, 1994
Bidwell JL, Bidwell EA, Savage DA, Middleton D, Klouda PT, Bradley BA: A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 45:640–646, 1988
Noreen HJ, Davidson ML, McCullough J, Bach FH, Segall M: HLA class II typing by restriction fragment length polymorphism (RFLP) in unrelated bone marow transplant patients. Transplant Proc 21:2968–2970, 1989
Mytilineos J, Scherer S, Oplez G: Comparison of RFLP-DR beta and serological HLA-DR typing in 1500 individuals. Transplantation 50:870–873, 1990
Bodmer JG, Marsh SGE, Albert ED, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasazuki T, Schreuder GMT, Strominger JL, Svejgaard A, Terasaki PI: Nomenclature for factors of the HLA system, 1991. Hum Immunol 34:4–18, 1992
Zetterquist H, Olerup O: Identification of the HLA-DRB1*04,-DRB1*07, and-DRB1*09 alleles by PCR amplication with sequence-specific primers (PCR-SSP) in 2 hours. Hum Immunol 34:64–74, 1992
Louzir H, Ternynck T, Gorgi Y, Tahar S, Ayed K, Avrameas S: Autoantibodies and circulating immune complexes in sera from patients with hepatitis B virus-related chronic liver disease. Clin Immunol Immunopathol 62:160–167, 1992
Eddleston ALWF, Mondelli M, Mieli-Vergani G, Williams R: Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. Hepatology 2:122S-127S, 1982
Eddleston ALWF, Williams R: Inadequate antibody response to HBs antigen or suppressor T-cell defect in the development of active chronic hepatitis. Lancet 2:1543–1548, 1974
Nouri-Aria KJ, Hegarty JE, Alexander GJM, Eddleston ALWF, Williams R: Effect of corticosteroids on suppressorcell activity in “autoimmune” and viral chronic active hepatitis. N Engl J Med 307:1301–1304, 1982
Hino K, Okuda M, Konishi T, Yamashita A, Kayano K, Kubota M, Yasunaga M, Fukumoto Y, Okita K: Analysis of lymphoid follicles in liver of patients with chronic hepatitis C. Liver 12:387–391, 1992
Mosnier J-F, Degott C, Marcellin P, Henin D, Erlinger S, Benhamou J-P: The intraportal lymphoid nodule and its environment in chronic active hepatitis C: An immunohistochemical study. Hepatology 17:366–371, 1993
Mosnier J-F, Scoazec J-Y, Marcellin P, Degott C, Benhamou J-P, Feldmann G: Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. Gastroenterology 107:1457–1468, 1994
Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Brunetto MR, Bonino F, Abrignani S: Compartmentalization of T lymphocytes to the site of disease: Intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis. C. J Exp Med 178:17–25, 1993
Fong T-L, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG: Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 107:196–199, 1994
Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L: Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 40:33–40, 1995
Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088–1094, 1994
Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Pescador R, Detmer J, Wilber JC, Pagliaro L: Hepatitis C viremia in chronic liver disease: Relationship to interferon-alpha or corticosteroid therapy. Hepatology 19:273–279, 1994
Yosioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T: Deterction of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus. Hepatology 16:293–299, 1992
Takada N, Takase S, Enomoto N, Takada A, Date T: Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 14:35–40, 1992
Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap P-L, Sherlock S, McIntyre N, Simmonds P: Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease. Hepatology 19:13–18, 1994
Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619–624, 1992
Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T: Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20:1121–1130, 1994
Czaja AJ, Taswell HF, Rakela J, Schimek C: Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. J Hepatol 14:88–93, 1992
Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PYH, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of communityacquired hepatitis C in the United States. N Engl J Med 327:1899–1905, 1992
Lok ASF, Cheung R, Chan R, Liu V: Hepatitis C viremia in patients with hepatitis C virus infection. Hepatology 15:1007–1012, 1992
Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Czaja, A.J., Carpenter, H.A., Santrach, P.J. et al. Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Digest Dis Sci 40, 2098–2106 (1995). https://doi.org/10.1007/BF02208990
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02208990